Development asset linked to Eisai in public FDA and regional records.
pharma · Non-small Cell Lung Cancer · Epilepsy
Eisai
Eisai Co.,
Eisai drug portfolio — 31 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Tokyo, Japan, JP HQ
41 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Tokyo, Japan, JP
- Employees
- 41
- Programs
- 22
- Drugs
- 31
- Patents
- 0
Eisai pipeline
Portfolio lens on 31 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Eisai drug portfolio — 31 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Eisai in public FDA and regional records.
-
Development asset linked to Eisai in public FDA and regional records.
-
Development asset linked to Eisai in public FDA and regional records.
-
bexarotene
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Retinoid X receptor.
- Target
- Retinoid X receptor
- Mechanism
- Retinoid X receptor agonist
-
Development asset linked to Eisai in public FDA and regional records.
-
Development asset linked to Eisai in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
carmustine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- Glutathione reductase inhibitor
-
doxorubicin
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Eisai's portfolio. Mechanism: DNA topoisomerase II alpha inhibitor.
- Mechanism
- DNA topoisomerase II alpha inhibitor
-
Development asset linked to Eisai in public FDA and regional records. Molecular target: Fibroblast growth factor receptor 1.
- Target
- Fibroblast growth factor receptor 1
- Mechanism
- Fibroblast growth factor receptor 1 inhibitor
-
eribulin
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Eisai's portfolio. Mechanism: Tubulin inhibitor.
- Mechanism
- Tubulin inhibitor
-
US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
erlotinib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Eisai's portfolio. Mechanism: Epidermal growth factor receptor erbB1 inhibitor.
- Mechanism
- Epidermal growth factor receptor erbB1 inhibitor
-
Development asset linked to Eisai in public FDA and regional records.
-
Development asset linked to Eisai in public FDA and regional records.
-
Development asset linked to Eisai in public FDA and regional records.
-
lecanemab
Nervous system (N06)Nervous system (N06) compound in Eisai's portfolio. Molecular target: Amyloid-beta precursor protein.
- Target
- Amyloid-beta precursor protein
- Mechanism
- Beta amyloid A4 protein inhibitor
-
lenvatinib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Eisai's portfolio. Mechanism: Vascular endothelial growth factor receptor inhibitor.
- Mechanism
- Vascular endothelial growth factor receptor inhibitor
-
US regulatory status: approved. Molecular target: Vascular endothelial growth factor receptor.
- Target
- Vascular endothelial growth factor receptor
- Mechanism
- Vascular endothelial growth factor receptor inhibitor
-
Development asset linked to Eisai in public FDA and regional records.
-
paclitaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
pembrolizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
perampanel
Nervous system (N03)US regulatory status: approved. Molecular target: Glutamate receptor ionotropic AMPA.
- Target
- Glutamate receptor ionotropic AMPA
- Mechanism
- Glutamate receptor ionotropic AMPA antagonist
-
Development asset linked to Eisai in public FDA and regional records.
-
Development asset linked to Eisai in public FDA and regional records.
-
Development asset linked to Eisai in public FDA and regional records.
-
Development asset linked to Eisai in public FDA and regional records.
-
Development asset linked to Eisai in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Histone-lysine N-methyltransferase EZH2.
- Target
- Histone-lysine N-methyltransferase EZH2
- Mechanism
- Histone-lysine N-methyltransferase EZH2 inhibitor
-
zonisamide
Nervous system (N03)US regulatory status: approved. Molecular target: Sodium channel alpha subunit.
- Target
- Sodium channel alpha subunit
- Mechanism
- Sodium channel alpha subunit blocker